Refine by
Coronavirus Covid Articles & Analysis
61 news found
Viral Vaccine Manufacturing to control pandemics: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) has created a global public health crisis. ...
ByNuvonis
Dr Richard Hatchett, CEO of CEPI, said: “Coronaviruses have now proven their pandemic potential with devastating consequences, and COVID-19 won’t be the last coronavirus to threaten humanity. That’s why CEPI’s ambitious programme to develop globally accessible vaccines that protect against a broad range of coronaviruses – before ...
Hospitals treating COVID-19 patients are looking to use the radar-based technology, previously used in heart-failure patients, to monitor lungs of coronavirus patients. Sensible Medical has recently received urgent requests from hospitals around the world for its ReDS monitors systems to improve monitoring, treatment and resource use for ...
Food and Drug Administrations (‘FDA’) for development of its lead antiviral drug BIT225 as a potential treatment of Coronavirus Disease 2019 (COVID-19) infection in adults. The FDA’s guidance was received in written response to Biotron’s pre-IND briefing package and request in March 2022, which included an overview of preclinical and ...
Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: uncertainties associated with the coronavirus (COVID-19) pandemic, including its possible effects on our operations, and the demand for our products; our ability to successfully ...
Submitted a proposal to the USA Food and Drug Administration to conduct a human clinical trial to assess the efficacy of BIT225 for the treatment of COVID-19 under the Coronavirus Treatment Acceleration Program, a special emergency program for potential coronavirus therapies. ...
COVID-19 and seasonal allergies have many of the same signs and symptoms. ...
The rising prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and increasing approval rate of abuse-deterrent formulations of opioid drugs are major driving factors of the global opioids drug market. The arrival of the coronavirus disease (COVID-19) pandemic ...
(POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory ...
The rising prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and increasing approval rate of abuse-deterrent formulations of opioid drugs are major driving factors of the global opioids drug market. The arrival of the coronavirus disease (COVID-19) pandemic ...
Executive Summary: At this time all Brentwood sites are operational. Our Indian facility reopened production this week, following a shutdown that was mandated by the Indian government. Our workforce is committed to continued support of our customers during the COVID-19 outbreak and our supply stream remains strong. As always we will get through this today, tomorrow, and ...
Food and Drug Administration (FDA) for a Phase 1 clinical study of MV-014-212, the company’s intranasal live attenuated chimeric vaccine candidate against SARS-CoV-2, the coronavirus that causes COVID-19. MV-014-212 offers significant potential advantages for COVID-19 vaccine global deployment, including needle-free intranasal ...
Environmental Protection Agency’s (EPA) Office of Enforcement and Compliance Assurance (OECA) announced that it issued a revised compliance advisory (Advisory) on products claiming to kill SARS-CoV-2, the novel coronavirus that causes COVID-19. EPA first issued this guidance on June 1, 2020, and it is discussed in our blog here. ...
The British Occupational Hygiene Society, a scientific charity and the Chartered Society for Worker Health Protection is issuing the following guidance on the mutations emerging to COVID-19 virus. Surveillance on mutations occurring in the COVID-19 virus has reported a number of mutations Data – COG-UK Consortium (cogconsortium.uk). ...
AKCP Coronavirus Vaccine Delivery Monitoring Solution The COVID-19 vaccines coming from Pfizer and Moderna both require storage and transportation at low temperatures. ...
ByAKCP
” If the approach can be proved further, it could make clinical research more efficient and value driven in elucidating other rare or novel diseases like coronavirus disease (COVID-19) with smaller patient populations. “Our research related to the coronavirus is in many ways a metaphor for all of our AI work, where one clinical ...
This announcement follows up on EPA’s October 14, 2020, announcement that it would begin expediting its review of products with residual efficacy intended for use against SARS-CoV-2, the coronavirus that causes COVID-19. While traditional disinfectants only kill viruses and bacteria that are on the surface at the time they are used, surfaces treated with ...
Environmental Protection Agency (EPA) released much-anticipated draft guidance that will allow companies to demonstrate that their products have “long-lasting” or “residual” effectiveness on surfaces against viruses like SARS-CoV-2, the coronavirus that causes COVID-19. As most know, EPA has not before now provided guidance on how ...
These are unprecedented times with the global outbreak of Coronavirus (COVID-19). We want our customers, partners, suppliers, employees and community to know that Anguil is following an existing, robust, business continuity plan for managing situations such as this. ...
This adds to a full line of top-quality Plexiglass Partitions and other isolation barriers to meet the needs of all industries to protect workers, customers and visitors and stop the spread of the Coronavirus. The Accu-Shield SG Clear Barrier Panels provide sneeze guard style protection through-out work areas in offices, warehouses and commercial settings with unobstructed ...